Zotepine - An antipsychotic with an atypical profile: Confirmation by recent pharmacological and clinical evaluations;Zotepin - Ein antipsychotikum mit atypischem profil: Bestatigung durch neuere pharmakologische und klinische untersuchungen

Psychopharmakotherapie

Volumn 7, Issue 2, 2000, Pages 70-74

  Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atypical antipsychotics; Zotepine

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; ZOTEPINE;

DRUG POTENCY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; PSYCHIATRIC TREATMENT; REVIEW;

EID: 1642586725     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa, 1993.
2. Barnas C, Tauscher J, Willeit M, et al. Visualisation of dopamine-2 receptor blockade in psychotic patients treated with zotepine. Eur Neuropsychopharmacol 1998;8(Suppl 2):S249-50.
3. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, et al. Effects of clozapine on positive and negative symptoms in out-patients with schizophrenia. Am J Psychiatry 1994;151:20-6.
4. Cooper SJ, et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Eur Neuropsychopharmacol 1998;8(Suppl 2):S232.
5. Cooper SJ, Tweed J, Raniwalla J, Butler A, et al. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand. Im Druck.
6. Gattaz WF, Schummer B, Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm 1998;96:227-32.
7. Heinrich K. Zotepin-Symposium Kyoto 1990. Fortschr Neurol Psychiatr 1991;59:1-56.
8. Holtom PE, Bennett, GW, Needham PL, et al. The atypical antipsychotic drugs, clozapine and zotepine differentially alter brain neurotensin binding when compared to haloperidol. Eur Neuropsychopharmacol 1998;8(Suppl 2): S247.
9. 2 receptors. Psychopharmacology 1993;112:40-52.
10. Loo H, Poirier-Littre MF, Theron M, Rein W, et al. Amisulpride versus placebo in the mediumterm treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22.
11. Marksteiner J, Mayr A, Fleischhacker WW, et al. Differential alterations in enkephalin mRNA expression in rat brain after chronic treatment with zotepine, clozapine and haloperidol. Eur Neuropsychopharmacol 1998;8 (Suppl 2):S240-1.
12. Möller HJ, Müller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenia patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245:45-9.
13. Möller HJ, Müller H. Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatry Clin Neurosci 1997;247:1-5.
14. Möller HJ, Müller N. Schizophrenie, moderne Konzepte zu Diagnostik, Pathogenese und Therapie. Berlin: Springer-Verlag, 1998.
15. Müller WE, Tuschl R, Gietzen K. Therapeutische und unerwünschte Wirkungen von Neuroleptika - die Bedeutung von Rezeptorprofilen: Zotepin im Vergleich zu Risperidon, Clozapin und Haloperidol. Psychopharmakotherapie 1995;2:148-53.
16. Needham PL, Atkinson J, Skill MJ, Heal DJ. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull 1996;32:123-8.
17. Overall JE, Gorham DR. BPRS. Brief Rating Scale. In: Guy W, editor. ECDEU assessment manual for psychopharmacology, rev. edn. Rockville: National Institute of Mental Health, 1976:157-69.
18. Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbations of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996;32:81-7.
19. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96: 265-73.
20. Prakash A, Lamb HM. Zotepine - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1998;9:153-75.
21. Rowley IC, et al. Zotepine elevates dopamine in the frontal cortex of freely-moving rats measured by in vivo microdialysis. Eur Neuropsychopharmacol 1998;8(Suppl 2):S241.
22. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124: 57-73.
23. Tollefson GD, Sanger TM. Negative symptoms: A path-analytical approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
24. Tweed JA, Wighton AJ, Ruck A, et al. The efficacy of zotepine in both long term and short term treatment of schizophrenia. 11. ECNP-Kongress, Paris, 1998.
25. th World Congress of Biological Psychiatry; 1997 June 22-27; Nice.
26. Wolfersdorf M, König F, Barg T. Monotherapie der wahnhaften Depression mit Zotepin. Psychopharmakotherapie 1997;4:149-52.
27. Zimbroff DL, Kane JM, Tamminga CA, et al. The Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91.